Home

GOLDMAN MYLA LAI

CIK 1168581 · EVP & Chief Medical Officer · last filed 2026-07-09

GOLDMAN MYLA LAI is an EVP & Chief Medical Officer who has filed 63 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for QTRX, was dated Jul 9, 2026. Across all open-market trades the lifetime net is −$6.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $16.2M across reported positions. 34 SEC filings were submitted jointly with LABORATORY CORP OF AMERICA HOLDINGS.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$16.18M

Companies

5

Total Filings

63

Lifetime Open-Market Net

-$6.85M

Filer Profile

Reported Address
3595 JOHN HOPKINS COURT
SAN DIEGO, CA 92121
Formerly Known As
GOLDMAN MYLA LAI (2002–2002)
Related Filers
LABORATORY CORP OF AMERICA HOLDINGS — 34 joint filings, latest 2008-11-24
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
QTRX Director 15,041 $2.56 $38.5K $0 4 2026-07-09
WST Director 20,434 $346.23 $7.08M $0 25 2026-05-06
Akoya Biosciences, Inc. (AKYA) Delisted Director 20,000 $1.29 $25.8K $100.0K 5 2024-06-05
SEQUENOM INC (SQNM) Delisted Director 0 — — $18.4K 10 2016-09-07
LH EVP & Chief Medical Officer 29,090 $311.54 $9.06M -$6.97M 18 2008-11-24

Recent Filings

63 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-09 QTRX Exer (M) +8,073 $0 EDGAR
2026-05-06 WST Grant (A) +791 $0 EDGAR
2026-01-06 QTRX Grant (A) +25,316 $0 EDGAR
2025-10-03 QTRX Grant (A) +2,084 $11.5K EDGAR
2025-07-10 — Other (J) −20,000 $0
2025-07-10 QTRX Grant (A) +27,404 $0 EDGAR
2025-05-08 WST Grant (A) +1,071 $0 EDGAR
2024-06-05 Akoya Biosciences, Inc. (AKYA) Delisted Grant (A) — $0 EDGAR
2024-04-25 WST Grant (A) +564 $0 EDGAR
2023-06-12 Akoya Biosciences, Inc. (AKYA) Delisted Buy (P) +20,000 $100.0K EDGAR
Showing 1–10 of 63
Page 1 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.